Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham S Taylor

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Infectious Agents and Cancer|March 12, 2026
Assessing T-cell responses to Epstein-Barr virus in individuals at risk for nasopharyngeal carcinomaWan-Lun Hsu, Chieh-Ju Lee, Anna E Coghill, et al.
Iscience|September 23, 2024
Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profilingEleni Syrimi, Naeem Khan, Paul Murray, et al.
The Journal of Experimental Medicine|May 19, 2004
CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1Steven P Lee, Jill M Brooks, Hatim Al-Jarrah, et al.
Nature Immunology|December 1, 2022
Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4<sup>+</sup> T cell recognitionEmily X C Tye, Elizabeth Jinks, Tracey A Haigh, et al.
Blood|July 31, 2010
A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyChristopher P Fox, Tracey A Haigh, Graham S Taylor, et al.
The Journal of Pathology|October 9, 2014
Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinomaLee Fah Yap, Sharmila Velapasamy, Hui Min Lee, et al.
Journal of Extracellular Vesicles|February 10, 2024
Bioengineered small extracellular vesicles deliver multiple SARS-CoV-2 antigenic fragments and drive a broad immunological responseHannah K Jackson, Heather M Long, Juan Carlos Yam-Puc, et al.
Cancer Research|January 26, 2013
Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patientsEdwin P Hui, Graham S Taylor, Hui Jia, et al.
The British Journal of Surgery|September 28, 2022
SARS-CoV-2 in the abdomen or pelvis: SAFE SURGERY studyDale Vimalachandran, Robert P Jones, Ed Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancerGraham S Taylor, Hui Jia, Kevin Harrington, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Infectious Agents and Cancer|March 12, 2026
Assessing T-cell responses to Epstein-Barr virus in individuals at risk for nasopharyngeal carcinomaWan-Lun Hsu, Chieh-Ju Lee, Anna E Coghill, et al.
Iscience|September 23, 2024
Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profilingEleni Syrimi, Naeem Khan, Paul Murray, et al.
The Journal of Experimental Medicine|May 19, 2004
CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1Steven P Lee, Jill M Brooks, Hatim Al-Jarrah, et al.
Nature Immunology|December 1, 2022
Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4<sup>+</sup> T cell recognitionEmily X C Tye, Elizabeth Jinks, Tracey A Haigh, et al.
Blood|July 31, 2010
A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyChristopher P Fox, Tracey A Haigh, Graham S Taylor, et al.
The Journal of Pathology|October 9, 2014
Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinomaLee Fah Yap, Sharmila Velapasamy, Hui Min Lee, et al.
Journal of Extracellular Vesicles|February 10, 2024
Bioengineered small extracellular vesicles deliver multiple SARS-CoV-2 antigenic fragments and drive a broad immunological responseHannah K Jackson, Heather M Long, Juan Carlos Yam-Puc, et al.
Cancer Research|January 26, 2013
Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patientsEdwin P Hui, Graham S Taylor, Hui Jia, et al.
The British Journal of Surgery|September 28, 2022
SARS-CoV-2 in the abdomen or pelvis: SAFE SURGERY studyDale Vimalachandran, Robert P Jones, Ed Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancerGraham S Taylor, Hui Jia, Kevin Harrington, et al.
Pageof 6